These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

59 related items for PubMed ID: 21229648

  • 1. ERCC1 is not expressed in hepatocellular cancer: A turkish oncology group, gastrointestinal oncology subgroup study.
    Turhal NS, Bas E, Er O, Aliustaoglu M, Seber S, Dane F, Korkmaz T, Soyuer I, Ozkara S, Celikel C.
    J BUON; 2010; 15(4):794-6. PubMed ID: 21229648
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma.
    Ueda S, Shirabe K, Morita K, Umeda K, Kayashima H, Uchiyama H, Soejima Y, Taketomi A, Maehara Y.
    Ann Surg Oncol; 2011 Apr; 18(4):1204-11. PubMed ID: 21076943
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma.
    Fautrel A, Andrieux L, Musso O, Boudjema K, Guillouzo A, Langouët S.
    J Hepatol; 2005 Aug; 43(2):288-93. PubMed ID: 15922480
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [Abstract] [Full Text] [Related]

  • 6. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R.
    J Clin Oncol; 2007 Jul 01; 25(19):2747-54. PubMed ID: 17602080
    [Abstract] [Full Text] [Related]

  • 7. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P.
    Clin Cancer Res; 2007 Jul 01; 13(13):3855-9. PubMed ID: 17606717
    [Abstract] [Full Text] [Related]

  • 8. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
    Liu GY, Qu QX, Mi RR, Qi J.
    Zhonghua Zhong Liu Za Zhi; 2008 Mar 01; 30(3):184-7. PubMed ID: 18756932
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Expression of human telomerase reverse transcriptase gene in HCC does not depend on proliferating cell nuclear antigen and P53].
    Zhang D, Li KZ, Dou KF, Gao ZQ, Song ZS, Zhao QC, Fu YC.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Nov 01; 20(6):721-2. PubMed ID: 15555445
    [Abstract] [Full Text] [Related]

  • 11. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
    Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S, Allolio B, Fassnacht M.
    Endocr Relat Cancer; 2009 Sep 01; 16(3):907-18. PubMed ID: 19240185
    [Abstract] [Full Text] [Related]

  • 12. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun 01; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.
    Zhonghua Zhong Liu Za Zhi; 2009 Jan 01; 31(1):33-7. PubMed ID: 19538866
    [Abstract] [Full Text] [Related]

  • 15. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival.
    Nakai S, Masaki T, Shiratori Y, Ohgi T, Morishita A, Kurokohchi K, Watanabe S, Kuriyama S.
    Int J Oncol; 2002 Apr 01; 20(4):769-75. PubMed ID: 11894123
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Proliferating cell nuclear antigen (PCNA) activity in hepatocellular carcinoma, benign peri-neoplastic and normal liver.
    Mun KS, Cheah PL, Baharudin NB, Looi LM.
    Malays J Pathol; 2006 Dec 01; 28(2):73-7. PubMed ID: 18376794
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Aberrant methylation of multiple genes and its clinical implication in hepatocellular carcinoma].
    Lou C, Yang B, Gao YT, Wang YJ, Nie FH, Yuan Q, Zhang CL, Du Z.
    Zhonghua Zhong Liu Za Zhi; 2008 Nov 01; 30(11):831-6. PubMed ID: 19173828
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.